Sunshine Biopharma, Inc.
SBFM
$1.51
-$0.04-2.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 34.87M | 32.96M | 30.48M | 26.74M | 24.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.87M | 32.96M | 30.48M | 26.74M | 24.09M |
| Cost of Revenue | 24.20M | 22.81M | 21.21M | 17.87M | 15.75M |
| Gross Profit | 10.67M | 10.14M | 9.27M | 8.87M | 8.34M |
| SG&A Expenses | 14.89M | 12.90M | 11.62M | 11.09M | 10.85M |
| Depreciation & Amortization | 223.50K | 200.50K | 173.10K | 157.10K | 149.20K |
| Other Operating Expenses | 387.00K | 355.00K | 351.10K | 301.90K | 289.70K |
| Total Operating Expenses | 40.64M | 37.87M | 35.07M | 31.07M | 28.90M |
| Operating Income | -5.76M | -4.91M | -4.59M | -4.33M | -4.81M |
| Income Before Tax | -5.37M | -4.11M | -3.74M | -3.72M | -4.11M |
| Income Tax Expenses | -234.80K | 114.20K | -60.00K | 371.40K | 395.30K |
| Earnings from Continuing Operations | -5.13 | -4.23 | -3.68 | -4.09 | -4.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.13M | -4.23M | -3.68M | -4.09M | -4.51M |
| EBIT | -5.76M | -4.91M | -4.59M | -4.33M | -4.81M |
| EBITDA | -5.54M | -4.71M | -4.41M | -4.17M | -4.66M |
| EPS Basic | -51.93 | -136.90 | -186.68 | -247.91 | -362.39 |
| Normalized Basic EPS | -36.27 | -79.87 | -109.10 | -138.72 | -208.08 |
| EPS Diluted | -51.93 | -136.90 | -186.68 | -247.91 | -362.48 |
| Normalized Diluted EPS | -36.27 | -79.87 | -109.10 | -138.72 | -208.08 |
| Average Basic Shares Outstanding | 3.50M | 1.36M | 109.10K | 72.10K | 51.00K |
| Average Diluted Shares Outstanding | 3.50M | 1.36M | 109.10K | 72.10K | 51.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |